Abstracted from
Trials Registry Platform. Additional hand searching of relevant journals and books of conference proceedings was undertaken.
Study selection Randomised and quasi-randomised controlled trials in people of all ages with haemophilia or VWD undergoing oral or dental procedures using antifibrinolytic agents (tranexamic acid (TXA) or epsilon aminocaproic acid (EACA)) to prevent perioperative bleeding compared to no intervention with or without placebo.
Data extraction and synthesis Two authors independently assessed identified publications for inclusion based on defined selection criteria. The two authors performed data extraction and risk of bias assessments using standardised forms and the Cochrane risk of bias tools. A third author, deemed to have particular subject expertise, verified eligibility of inclusion.
Results One randomised, double-blinded placebo controlled trial and one quasi-randomised trial were included. A total of 59 participants with haemophilia undergoing dental extraction were involved. Both trials evidenced a notable reduction in post-operative bleeding following dental extraction when either TXA or EACA were used, in addition to routine preoperative factor replacement, when compared Safe and successful patient-centred management for people with inherited bleeding disorders requires collaborative multidisciplinary working between haematology and dental teams.
The severity of the bleeding disorder will influence the level of medical intervention necessary to ensure the safe delivery of dental care. Defective coagulation may require the utilisation of factor concentrate or desmopressin in addition to local haemostatic techniques and the appropriate use of antifibrinolytic agents to prevent catastrophic bleeds following haemostatic challenges including dental intervention.
The use of factor replacement therapy is associated with risks including the transmission of blood borne viruses and the development of inhibitors or antibodies. 3 The latter risk negates further use of factor replacement as a consequence of immune mediated response. It is desirable to minimise the use of replacement factor from both a risk and cost perspective.
Thus strategies to prevent dental disease and reduce the risk of This paper is based on a Cochrane Review published in the Cochrane Library 2015, issue 12 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the most recent version of the review. The haemophilia studies included in the review 5,6 display significant heterogeneity across sample size and intervention methodologies. In both studies all participants received factor replacement prior to dental extraction, therefore it can be assumed that antifibrinolytic therapy is not a replacement for appropriate levels of factor to facilitate haemostasis. Due to small sample sizes, participants with mild, moderate and severe disease were combined into a single group for analysis in both studies. The lack of discrimination between severity of disease and outcome with intervention hinders the clinical implications of the research presented.
Furthermore, the studies varied in the antifibrinolytic agent used, the dosing and frequency of agent used, whilst in one study dental extractions were performed under general anaesthetic and in the other with the use of local anaesthetic. Moreover, the additional use of an acrylic plate to protect the formed clot may have masked the true effect of the EACA. Additionally, the authors of the review highlighted the potential risk of bias in this study.
Such discord between study design inhibits the ability to truly compare data and subsequently inform evidence-based practice.
The quality of evidence which currently exists to inform the recommended use of adjuvant antifibrinolytic therapy in the management of patients with inherited bleeding disorders undergoing dental extraction is poor. Nevertheless, despite the limitations there does appear to be a benefit in the use of adjuvant therapy to reduce perioperative bleeding with no significant side effects of the therapy encountered. At present, clinicians should conform to existing guidelines which recommend the use of adjuvant antifibrinolytic therapy. 6 However, the research and clinical community involved in the care of people with inherited bleeding disorders are encouraged to seek higher quality evidence from which to inform management strategies. 
